

## APC anti-human CD4 Antibody

<b>Catalog# / Size</b>	300514 / 100 tests 300552 / 100 µg 300537 / 500 tests
<b>Clone</b>	RPA-T4
<b>Regulatory Status</b>	RUO
<b>Workshop</b>	IV T114
<b>Other Names</b>	T4
<b>Isotype</b>	Mouse IgG1, κ
<b>Description</b>	CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

### Product Details

---

<b>Verified Reactivity</b>	Human
<b>Reported Reactivity</b>	Chimpanzee
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Formulation</b>	µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections <sup>3,4,5</sup> , blocking of T cell activation <sup>1,2</sup> , and spatial biology (IBEX) <sup>10,11</sup> . This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).
<b>Application References</b>	1. Knapp W, <i>et al.</i> 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
<b>(PubMed link indicates</b>	2. Moir S, <i>et al.</i> 1999. <i>J. Virol.</i> 73:7972. (Activ)

**BioLegend citation)**

3. Deng MC, *et al.* 1995. *Circulation* 91:1647. (IHC)
4. Friedman T, *et al.* 1999. *J. Immunol.* 162:5256. (IHC)
5. Mack CL, *et al.* 2004. *Pediatr. Res.* 56:79. (IHC)
6. Lan RY, *et al.* 2006. *Hepatology* 43:729.
7. Zenaro E, *et al.* 2009. *J. Leukoc. Biol.* 86:1393. (FC) [PubMed](#)
8. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
9. Stoeckius M, *et al.* 2017. *Nat. Methods.* 14:865. (PG)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci USA.* 117:33455-33465. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

**Product Citations**

1. Tang M, *et al.* 2019. *Biomed Res Int.* 2019:1050285. [PubMed](#)
2. Cao B, *et al.* 2022. *Nat Commun.* 13:6203. [PubMed](#)
3. Penkava F, *et al.* 2020. *Nat Commun.* 3.76875. [PubMed](#)
4. Nakano Y, *et al.* 2017. *PLoS Pathog.* 13:e1006348. [PubMed](#)
5. Carpenter RS, *et al.* 2019. *Sci Rep.* 9:19105. [PubMed](#)
6. Wang F, *et al.* 2018. *Oncogenesis.* 7:41. [PubMed](#)
7. Eleftheriadis T, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
8. Schmidleithner L *et al.* 2019. *Immunity.* 50(5):1232-1248 . [PubMed](#)
9. Koelsch K, *et al.* 2013. *PLoS One.* 8:50068. [PubMed](#)
10. Tang-Huau TL, *et al.* 2018. *Nat Commun.* 9:2570. [PubMed](#)
11. Eri Yamada *et al.* 2018. *Cell host & microbe.* 23(1):110-120 . [PubMed](#)
12. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283 . [PubMed](#)
13. Park JA, *et al.* 2021. *J Hematol Oncol.* 14:142. [PubMed](#)
14. Gludish DW, *et al.* 2020. *Sci Rep.* 10:19900. [PubMed](#)
15. Fletcher H, *et al.* 2016. *Nat Commun.* 7: 11290. [PubMed](#)
16. Stuart T, *et al.* 2019. *Cell.* 177:1888. [PubMed](#)
17. Kim ST, *et al.* 2022. *Nat Commun.* 13:1970. [PubMed](#)
18. Kobayashi Y, *et al.* 2020. *Int J Oncol.* 999:56. [PubMed](#)
19. Vyborova A, *et al.* 2022. *Front Immunol.* 13:915366. [PubMed](#)
20. Kerstein A, *et al.* 2016. *J Autoimmun.* S0896-8411(16)30186-X. [PubMed](#)
21. Ng CY, *et al.* 2022. *EMBO Rep.* 23:e54271. [PubMed](#)
22. Jancewicz I, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
23. Martin Monreal MT, *et al.* 2021. *Front Immunol.* 12:716250. [PubMed](#)
24. Souriant S, *et al.* 2019. *Cell Rep.* 26:3586. [PubMed](#)
25. Lu Y, *et al.* 2021. *Gastroenterology.* 161:575. [PubMed](#)
26. Idorn M, *et al.* 2018. *Oncoimmunology.* 7:e1412029. [PubMed](#)
27. Kacherovsky N, *et al.* 2019. *Nat Biomed Eng.* 0.66875. [PubMed](#)
28. André M, *et al.* 2010. *J Immunol.* 185:2710. [PubMed](#)
29. Reichwald K, *et al.* 2014. *PLoS One.* 9:105627. [PubMed](#)
30. Usero L, *et al.* 2016. *Diabetes.* 65: 2356 - 2366. [PubMed](#)
31. Park MJ, *et al.* 2019. *J Immunol.* 203:127. [PubMed](#)
32. Zuccato C, *et al.* 2022. *Ther Adv Hematol.* 13:20406207221100648. [PubMed](#)
33. Kim D, *et al.* 2020. *Nat Med.* 26:236. [PubMed](#)
34. Chulpanova DS, *et al.* 2021. *Biology (Basel).* 10:. [PubMed](#)
35. Huber JE, *et al.* 2020. *J Immunol.* 204:1101. [PubMed](#)
36. Lundy SK, *et al.* 2018. *Front Med (Lausanne).* 0.38125. [PubMed](#)
37. O'Leary CE, *et al.* 2021. *Curr Protoc.* 1:e77. [PubMed](#)
38. Iwata A, *et al.* 2017. *Nat Immunol.* 18:563. [PubMed](#)
39. Lotfi S, *et al.* 2020. *Retrovirology.* 17:20. [PubMed](#)
40. Ng CY, *et al.* 2022. *EMBO Rep.* 23:e55871. [PubMed](#)
41. Cui J, *et al.* 2019. *Neuro Oncol.* 21:1436. [PubMed](#)
42. Beyer AI, *et al.* 2017. *Stem Cells Dev.* 26:102. [PubMed](#)
43. Huang LJ, *et al.* 2021. *Immunity.* 54(8):1728-1744.e7. [PubMed](#)
44. Dyson MR, *et al.* 2020. *MAbs.* 12:1829335. [PubMed](#)
45. Koh WH, *et al.* 2020. *STAR Protoc.* 1:100203. [PubMed](#)
46. Martin GE, *et al.* 2018. *Front Immunol.* 1.019444444. [PubMed](#)
47. Ma S, *et al.* 2022. *Nat Commun.* 13:4118. [PubMed](#)
48. Li B, *et al.* 2019. *Oncogenesis.* 8:17. [PubMed](#)
49. Chang XL, *et al.* 2021. *Nat Commun.* 12:3343. [PubMed](#)
50. Pawlicki JM, *et al.* 2021. *Cancer Res.* 81:3241. [PubMed](#)
51. Olety B, *et al.* 2021. *Sci Adv.* 7:eabj7398. [PubMed](#)

**RRID**

AB\_314082 (BioLegend Cat. No. 300514)  
AB\_2564153 (BioLegend Cat. No. 300552)  
AB\_2562051 (BioLegend Cat. No. 300537)

**Antigen Details**

---

<b>Structure</b>	Ig superfamily, type I transmembrane glycoprotein, 55 kD
<b>Distribution</b>	T cell subset, majority of thymocytes, monocytes/macrophages
<b>Function</b>	MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
<b>Ligand/Receptor</b>	MHC class II molecules, HIV gp120, IL-16

<b>Cell Type</b>	Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Center D, <i>et al.</i> 1996. <i>Immunol. Today</i> 17:476. 2. Gaubin M, <i>et al.</i> 1996. <i>Eur. J. Clin. Chem. Clin. Biochem.</i> 34:723.
<b>Gene ID</b>	<a href="#">920</a>

## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-human CD4, Biotin anti-human CD4, FITC anti-human CD4, PE anti-human CD4, PE/Cyanine5 anti-human CD4, PE/Cyanine7 anti-human CD4, Purified anti-human CD4, APC/Cyanine7 anti-human CD4, Alexa Fluor® 488 anti-human CD4, Alexa Fluor® 647 anti-human CD4, Pacific Blue™ anti-human CD4, Brilliant Violet 421™ anti-human CD4, Alexa Fluor® 700 anti-human CD4, PerCP anti-human CD4, PerCP/Cyanine5.5 anti-human CD4, Brilliant Violet 570™ anti-human CD4, Brilliant Violet 650™ anti-human CD4, Purified anti-human CD4 (Maxpar® Ready), Alexa Fluor® 594 anti-human CD4, Brilliant Violet 510™ anti-human CD4, PE/Dazzle™ 594 anti-human CD4, Brilliant Violet 785™ anti-human CD4, Brilliant Violet 605™ anti-human CD4, Brilliant Violet 711™ anti-human CD4, APC/Fire™ 750 anti-human CD4, CD4 Fluorophore Sampler Kit, CD4 Fluorophore Sampler Kit with Veri-Cells™ PBMC, TotalSeq™-A0072 anti-human CD4, TotalSeq™-B0072 anti-human CD4, TotalSeq™-C0072 anti-human CD4, Ultra-LEAF™ Purified anti-human CD4, TotalSeq™-D0072 anti-human CD4

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587